PDGFRa (V561D)
Sign in to save this workspacePDGFRA · Variant type: point · HGVS: p.V561D
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 99.7% | 0.3% | 78.23 |
| 2 | Nilotinib | 98.6% | 1.4% | 96.49 |
| 3 | Avapritinib | 98.3% | 1.7% | 97.73 |
| 4 | Sorafenib | 98.2% | 1.8% | 96.72 |
| 5 | Dasatinib | 98.2% | 1.8% | 87.97 |
| 6 | Tivozanib | 97.4% | 2.6% | 92.42 |
| 7 | Nintedanib | 96.9% | 3.1% | 90.23 |
| 8 | Imatinib | 96.9% | 3.1% | 99.00 |
| 9 | Axitinib | 94.8% | 5.2% | 93.23 |
| 10 | Regorafenib | 94.3% | 5.7% | 95.99 |
| 11 | Erdafitinib | 90.8% | 9.2% | 95.71 |
| 12 | Lenvatinib | 87.5% | 12.5% | 97.74 |
| 13 | Sunitinib | 84.7% | 15.3% | 91.73 |
| 14 | Cabozantinib | 84.3% | 15.8% | 92.73 |
| 15 | Ripretinib | 82.3% | 17.7% | 92.95 |
| 16 | Selpercatinib | 82.1% | 17.9% | 96.72 |
| 17 | Pazopanib | 79.5% | 20.5% | 97.49 |
| 18 | Quizartinib | 78.7% | 21.3% | 99.50 |
| 19 | Pexidartinib | 71.6% | 28.4% | 99.49 |
| 20 | Vandetanib | 71.3% | 28.7% | 95.74 |
| 21 | Apatinib | 70.5% | 29.5% | 97.73 |
| 22 | Vemurafenib | 70.0% | 30.0% | 96.49 |
| 23 | Fedratinib | 69.2% | 30.8% | 96.21 |
| 24 | Umbralisib | 66.2% | 33.8% | 98.74 |
| 25 | Brigatinib | 66.0% | 34.0% | 82.96 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 99.7% | 100.0% | -0.3% |
| Nilotinib | 98.6% | 97.9% | +0.7% |
| Avapritinib | 98.3% | 99.1% | -0.9% |
| Sorafenib | 98.2% | 95.6% | +2.6% |
| Dasatinib | 98.2% | 98.3% | -0.1% |
| Tivozanib | 97.4% | 96.9% | +0.5% |
| Nintedanib | 96.9% | 98.3% | -1.4% |
| Imatinib | 96.9% | 98.9% | -2.0% |
| Axitinib | 94.8% | 96.0% | -1.2% |
| Regorafenib | 94.3% | 96.7% | -2.3% |
| Erdafitinib | 90.8% | 94.5% | -3.7% |
| Lenvatinib | 87.5% | 88.0% | -0.5% |
| Sunitinib | 84.7% | 84.2% | +0.5% |
| Cabozantinib | 84.3% | 79.3% | +5.0% |
| Ripretinib | 82.3% | 81.5% | +0.8% |
| Selpercatinib | 82.1% | — | — |
| Pazopanib | 79.5% | 74.5% | +5.0% |
| Quizartinib | 78.7% | — | — |
| Pexidartinib | 71.6% | — | — |
| Vandetanib | 71.3% | 82.0% | -10.7% |
| Apatinib | 70.5% | — | — |
| Vemurafenib | 70.0% | — | — |
| Fedratinib | 69.2% | — | — |
| Umbralisib | 66.2% | — | — |
| Brigatinib | 66.0% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| gastrointestinal_stromal_tumour_soft_tissue | Soft Tissue | ref |
| other_stomach | Stomach/Digestive Tract | ref |
| other_small_intestine | Small Intestine | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.6ms